Tesamorelin cost: what it is, and what we will not pretend to know
What we evaluated: publicly advertised pricing for Tesamorelin across telehealth and longevity providers
Date verified: July 12, 2026
Direct answer: We do not publish a price for Tesamorelin, because we have not verified one. Telehealth and longevity clinics advertise widely varying figures, and we have not captured and dated them against provider sources under our pricing-verification methodology. Publishing an unverified number would be worse than publishing none.
Necessary qualification: we label an unverified price as unverified rather than publishing a plausible-looking number
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
How Tesamorelin differs from the alternatives
Tesamorelin versus sermorelin — and the trap inside tesamorelin's approval. Tesamorelin is the only peptide on this site with a current FDA approval (Egrifta), which sets it apart from sermorelin, whose only approved product (Geref) was discontinued.
But that approval is narrow, and the narrowness is where people get misled. Egrifta is approved for one thing: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general fat loss, body composition in healthy adults, anti-ageing or athletic performance — and there is no comparable trial evidence for any of those.
Worse, the tesamorelin most longevity clinics dispense is compounded, which means it is not the FDA-approved product and carries none of that regulatory assurance. 'Tesamorelin is FDA-approved' is a true sentence that is being used to sell you something the approval does not cover. Ask explicitly: am I receiving Egrifta, or a compounded preparation?
The cost picture
Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.
| Field | Status |
|---|---|
| Advertised price | Evaluation in progress Verification pending — we have not captured it |
| Membership / consultation fees | Evaluation in progress Not publicly disclosed in a form we can verify |
| FDA status | Verified See our Tesamorelin evidence page |
| Human clinical evidence | Verified Reviewed and graded on the Tesamorelin page |
| Safety profile | Verified Reviewed on the Tesamorelin page |
What we can tell you is what the evidence supports, what the FDA has and has not approved, and what questions to ask before you pay anyone anything. That is on the Tesamorelin page, and it matters more than a price.
Before you consider price, consider evidence
What to ask before paying anyone
- What specific outcome are we targeting, and how will we measure whether it worked?
- What is the human evidence for that outcome — not the mechanism, the outcome?
- Is this compounded? By which state-licensed pharmacy?
- What is the total cost including consultation, follow-up and any required labs?
- What happens if it does not work — is there a point at which we stop?
Frequently asked questions
What does Tesamorelin cost?
We have not verified a market price. On October 15, 2026, the Egrifta WR website published no list price, describing co-pay and patient assistance programs instead, and Oak Longevity priced tesamorelin only after an assessment. Ask for the total cost in writing, and ask whether you will get Egrifta WR or a compounded product.
Is Tesamorelin FDA-approved?
Yes, for one use. Egrifta WR is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, and its label says it is not indicated for weight-loss management. Compounded tesamorelin is not the approved product, and other uses are off-label.
Why publish a cost page with no cost?
Because the most useful thing we can tell you about this treatment's price is that nobody has verified it — and that the evidence for the treatment itself is weaker than the marketing implies.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance.
- PubMed / NIH — indexed human clinical literature.
- Our pricing-verification methodology and source policy.